Finding 528298 (2024-002)

Significant Deficiency Repeat Finding
Requirement
L
Questioned Costs
-
Year
2024
Accepted
2025-03-17

AI Summary

  • Core Issue: Lack of proper supervisory review and approval for grant reporting increases the risk of errors.
  • Impacted Requirements: Effective internal controls require timely and documented supervisory reviews.
  • Recommended Follow-Up: Ensure the Treasurer reviews and documents approval of all future grant reports before submission.

Finding Text

2024-002 – CONTROLS OVER GRANT REPORTING (93.788 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES) Condition: The Association does not have appropriate supervisory review and approval procedures in the grant reporting function within the internal control framework. Criteria: Effective internal control over compliance includes appropriate, timely, and documented supervisory review and approval procedures. Cause: The grant reporting is prepared and submitted by the program manager without documented supervisory review and approval. Effect: The Association is at an increased risk for grant reporting errors or omissions without timely supervisory review and approval. Questioned Costs: N/A Recommendation: We recommend the Treasurer review and approve all future grant reports prior to their submission. The approval should be documented in writing. Views of Responsible Officials: Management concurs with the finding and has developed a plan to correct the finding.

Corrective Action Plan

CONTROLS OVER GRANT REPORTING Department of Health and Human Services 93.788 Management within West Virginia Public Transit Association appreciates and shares the auditors' concern with integrity as it relates to controls over grant reporting. The State Opioid Response Transportation Project Manager will submit all future grant reports to a member of the West Virginia Public Transit Association Board. This approval will be documented in writing.

Categories

Reporting Internal Control / Segregation of Duties

Other Findings in this Audit

  • 528297 2024-001
    - Repeat
  • 528299 2024-001
    - Repeat
  • 528300 2024-002
    Significant Deficiency Repeat
  • 1104739 2024-001
    - Repeat
  • 1104740 2024-002
    Significant Deficiency Repeat
  • 1104741 2024-001
    - Repeat
  • 1104742 2024-002
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $3.74M